Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282166 | 0.84 | TACR1 (0.36) | TACR1AGTR2OPRK1 | |
| SCHEMBL4285211 | 0.76 | CA1 (0.39) | MEN1KMT2ANLRP3OPRK1 | |
| SCHEMBL28978003 | 0.76 | ACHE (0.50) | MEN1KMT2A | |
| SCHEMBL13705270 | 0.75 | PARP1 (0.56) | MEN1KMT2AOPRK1 | |
| SCHEMBL4282201 | 0.74 | MAN1B1 (0.38) | AGTR2 | |
| SCHEMBL4281174 | 0.74 | ALDH1A1 (0.46) | MEN1KMT2A | |
| SCHEMBL3494366 | 0.74 | TEAD1 (0.50) | MEN1KMT2A | |
| SCHEMBL4284550 | 0.73 | TEAD1 (0.46) | MEN1KMT2A | |
| SCHEMBL4281759 | 0.73 | RAB9A (0.46) | KMT2A | |
| SCHEMBL4297127 | 0.72 | CA1 (0.36) | TACR1MEN1KMT2AAGTR2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | TACR1 97/4885MEN1 1254/4885KMT2A 1049/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | TACR1 97/4885MEN1 1254/4885KMT2A 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.